2020 欧洲共识声明:G4-G5D期慢性肾脏病患者骨质疏松的诊断和管理

2020-10-24 欧洲肾脏学会-欧洲透析和移植学会 Nephrol Dial Transplant . 2020 Oct 24;

控制G4-G5D期慢性肾脏病患者过度的骨折负担仍充满挑战,本文主要针对G4-G5D期慢性肾脏病患者骨质疏松的诊断和管理提供共识建议。

中文标题:

2020 欧洲共识声明:G4-G5D期慢性肾脏病患者骨质疏松的诊断和管理

英文标题:

European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4-G5D

发布日期:

2020-10-24

简要介绍:

控制G4-G5D期慢性肾脏病患者过度的骨折负担仍充满挑战,本文主要针对G4-G5D期慢性肾脏病患者骨质疏松的诊断和管理提供共识建议。

 

相关资料下载:
[AttachmentFileName(sort=1, fileName=2020 欧洲共识声明:G4-G5D期慢性肾脏病患者骨质疏松的诊断和管理.pdf)] GetToolGuiderByIdResponse(projectId=1, id=eafd91c00200364a, title=2020 欧洲共识声明:G4-G5D期慢性肾脏病患者骨质疏松的诊断和管理, enTitle=European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4-G5D, guiderFrom=Nephrol Dial Transplant . 2020 Oct 24;, authorId=0, author=, summary=控制G4-G5D期慢性肾脏病患者过度的骨折负担仍充满挑战,本文主要针对G4-G5D期慢性肾脏病患者骨质疏松的诊断和管理提供共识建议。, cover=https://img.medsci.cn/20201031/1604152081999_2020535.jpg, journalId=0, articlesId=null, associationId=711, associationName=欧洲肾脏学会-欧洲透析和移植学会, associationIntro=null, copyright=0, guiderPublishedTime=Sat Oct 24 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>控制G4-G5D期慢性肾脏病患者过度的骨折负担仍充满挑战,本文主要针对G4-G5D期慢性肾脏病患者骨质疏松的诊断和管理提供共识建议。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=2527, tagName=慢性肾脏病)], categoryList=[CategoryDto(categoryId=10, categoryName=骨科, tenant=100), CategoryDto(categoryId=14, categoryName=肾内科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21067, categoryName=梅斯医学-骨质疏松网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=2527, guiderKeyword=慢性肾脏病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3610, appHits=162, showAppHits=0, pcHits=903, showPcHits=3447, likes=1, shares=16, comments=11, approvalStatus=1, publishedTime=Sat Oct 31 23:09:20 CST 2020, publishedTimeString=2020-10-24, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Sat Oct 31 21:48:31 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Tue Jan 02 18:36:02 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 欧洲共识声明:G4-G5D期慢性肾脏病患者骨质疏松的诊断和管理.pdf)])
2020 欧洲共识声明:G4-G5D期慢性肾脏病患者骨质疏松的诊断和管理.pdf
下载请点击:
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=897509, encodeId=b3a289e50900, content=评论得积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201030/42cd5653f1304c9ba6070e588265b72d/e52b07d53dff40b1a0cf9dfe3218b3a8.jpg, createdBy=64735429102, createdName=Hangman, createdTime=Sat Nov 07 09:05:07 CST 2020, time=2020-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214739, encodeId=a0d11214e39c6, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 19:50:07 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919541, encodeId=adae9195411a, content=好共识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201220/0fc988a64b15412ebc01f1037f0bba09/ef3f4a4ee2574056b28808db1a70a6db.jpg, createdBy=69f85432203, createdName=淼淼鑫, createdTime=Sun Jan 24 21:19:26 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901491, encodeId=030490149106, content=好共识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ee65437734, createdName=ms1000001932393738, createdTime=Mon Nov 23 16:36:38 CST 2020, time=2020-11-23, status=1, ipAttribution=)]
    2020-11-07 Hangman

    评论得积分

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=897509, encodeId=b3a289e50900, content=评论得积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201030/42cd5653f1304c9ba6070e588265b72d/e52b07d53dff40b1a0cf9dfe3218b3a8.jpg, createdBy=64735429102, createdName=Hangman, createdTime=Sat Nov 07 09:05:07 CST 2020, time=2020-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214739, encodeId=a0d11214e39c6, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 19:50:07 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919541, encodeId=adae9195411a, content=好共识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201220/0fc988a64b15412ebc01f1037f0bba09/ef3f4a4ee2574056b28808db1a70a6db.jpg, createdBy=69f85432203, createdName=淼淼鑫, createdTime=Sun Jan 24 21:19:26 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901491, encodeId=030490149106, content=好共识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ee65437734, createdName=ms1000001932393738, createdTime=Mon Nov 23 16:36:38 CST 2020, time=2020-11-23, status=1, ipAttribution=)]
    2022-04-26 su_yi_fei

    很实用

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=897509, encodeId=b3a289e50900, content=评论得积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201030/42cd5653f1304c9ba6070e588265b72d/e52b07d53dff40b1a0cf9dfe3218b3a8.jpg, createdBy=64735429102, createdName=Hangman, createdTime=Sat Nov 07 09:05:07 CST 2020, time=2020-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214739, encodeId=a0d11214e39c6, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 19:50:07 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919541, encodeId=adae9195411a, content=好共识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201220/0fc988a64b15412ebc01f1037f0bba09/ef3f4a4ee2574056b28808db1a70a6db.jpg, createdBy=69f85432203, createdName=淼淼鑫, createdTime=Sun Jan 24 21:19:26 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901491, encodeId=030490149106, content=好共识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ee65437734, createdName=ms1000001932393738, createdTime=Mon Nov 23 16:36:38 CST 2020, time=2020-11-23, status=1, ipAttribution=)]
    2021-01-24 淼淼鑫

    好共识

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=897509, encodeId=b3a289e50900, content=评论得积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201030/42cd5653f1304c9ba6070e588265b72d/e52b07d53dff40b1a0cf9dfe3218b3a8.jpg, createdBy=64735429102, createdName=Hangman, createdTime=Sat Nov 07 09:05:07 CST 2020, time=2020-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214739, encodeId=a0d11214e39c6, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 19:50:07 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919541, encodeId=adae9195411a, content=好共识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201220/0fc988a64b15412ebc01f1037f0bba09/ef3f4a4ee2574056b28808db1a70a6db.jpg, createdBy=69f85432203, createdName=淼淼鑫, createdTime=Sun Jan 24 21:19:26 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901491, encodeId=030490149106, content=好共识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ee65437734, createdName=ms1000001932393738, createdTime=Mon Nov 23 16:36:38 CST 2020, time=2020-11-23, status=1, ipAttribution=)]
    2020-11-23 ms1000001932393738

    好共识

    0

拓展阅读

2015慢性肾脏病评估及管理临床实践指南解读——从 K/DOQI 到 KDIGO

国际肾脏病学会(ISN,International Society of Nephrology) · 2016-04-25

慢性肾脏病筛查诊断及防治指南

肾脏病相关专家小组(统称) · 2017-01-30

HIV感染合并慢性肾脏病患者管理专家共识

中国感染病相关专家组(统称) · 2017-06-15